Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide

Journal of Immunology

Volumn 189, Issue 12, 2012, Pages 5498-5502

  Morrison, Brad E ^a   Marcondes, Maria Cecilia Garibaldi ^a   Nomura, Daniel K ^a   Sanchez Alavez, Manuel ^a   Sanchez Gonzalez, Alejandro ^a   Saar, Indrek ^a   Kim, Kwang Soo ^b   Bartfai, Tamas ^a   Maher, Pamela ^c   Sugama, Shuei ^d   Conti, Bruno ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; HYDROGEN PEROXIDE; HYDROPEROXIDE; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL LOSS; CYTOTOXICITY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; INFLAMMATION; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA; X CHROMOSOME;

ANIMALS; CELL DEATH; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENETIC DISEASES, X-LINKED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84871121078     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102150     Document Type: Article

References (42)

1. de Lau, L. M., and M. M. Breteler. 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5: 525-535. (Pubitemid 44262284)
2. Lesage, S., and A. Brice. 2009. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18(R1): R48-R59.
3. Kasten, M., A. Chade, and C. M. Tanner. 2007. Epidemiology of Parkinson's disease. Handb. Clin. Neurol. 83: 129-151.
4. Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
5. Scott, W. K., M. A. Nance, R. L. Watts, J. P. Hubble, W. C. Koller, K. Lyons, R. Pahwa, M. B. Stern, A. Colcher, B. C. Hiner, et al. 2001. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286: 2239-2244. (Pubitemid 33063145)
6. Pankratz, N., W. C. Nichols, S. K. Uniacke, C. Halter, A. Rudolph, C. Shults, P. M. Conneally, and T. Foroud; Parkinson Study Group. 2002. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71: 124-135. (Pubitemid 34734713)
7. Ramalingam, T. R., J. T. Pesce, F. Sheikh, A. W. Cheever, M. M. Mentink-Kane, M. S. Wilson, S. Stevens, D. M. Valenzuela, A. J. Murphy, G. D. Yancopoulos, et al. 2008. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor a1 chain. Nat. Immunol. 9: 25-33. (Pubitemid 350286200)
8. Munitz, A., E. B. Brandt,M. Mingler, F. D. Finkelman, and M. E. Rothenberg. 2008. Distinct roles for IL-13 and IL-4 via IL-13 receptor a1 and the type II IL-4 receptor in asthma pathogenesis. Proc. Natl. Acad. Sci. USA 105: 7240-7245. (Pubitemid 351754462)
9. Murata, T., P. D. Noguchi, and R. K. Puri. 1996. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J. Immunol. 156: 2972-2978. (Pubitemid 126660646)
10. Conti, B., M. Sanchez-Alavez, R. Winsky-Sommerer, M. C. Morale, J. Lucero, S. Brownell, V. Fabre, S. Huitron-Resendiz, S. Henriksen, E. P. Zorrilla, et al. 2006. Transgenic mice with a reduced core body temperature have an increased life span. Science 314: 825-828. (Pubitemid 44706650)
11. Conti, B., S. Sugama, J. Lucero, R. Winsky-Sommerer, S. A. Wirz, P. Maher, Z. Andrews, A. M. Barr, M. C. Morale, C. Paneda, et al. 2005. Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl- tetrahydropyridine toxicity. J. Neurochem. 93: 493-501. (Pubitemid 40547506)
12. Sugama, S., S. A. Wirz, A. M. Barr, B. Conti, T. Bartfai, and T. Shibasaki. 2004. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine treatment. Neuroscience 128: 451-458. (Pubitemid 39200490)
13. Frank-Cannon, T. C., T. Tran, K. A. Ruhn, T. N. Martinez, J. Hong, M. Marvin, M. Hartley, I. Treviño, D. E. O'Brien, B. Casey, et al. 2008. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 28: 10825-10834.
14. Erickson, M. A., and W. A. Banks. 2011. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav. Immun. 25: 1637-1648.
15. Kovac, A., M. A. Erickson, and W. A. Banks. 2011. Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide. J. Neuroinflammation 8: 139.
16. Uhl, G. R., J. C. Hedreen, and D. L. Price. 1985. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35: 1215-1218. (Pubitemid 15003464)
17. Di Monte, D. A., M. Lavasani, and A. B. Manning-Bog. 2002. Environmental factors in Parkinson's disease. Neurotoxicology 23: 487-502. (Pubitemid 36527669)
18. Henchcliffe, C., and M. F. Beal. 2008. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4: 600-609.
19. Jenner, P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13(Suppl. 1): 24-34.
20. Parker, W. D., Jr., and R. H. Swerdlow. 1998. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 62: 758-762.
21. Tan, J. M., E. S. Wong, and K. L. Lim. 2009. Protein misfolding and aggregation in Parkinson's disease. Antioxid. Redox Signal. 11: 2119-2134.
22. Block, M. L., and J. S. Hong. 2007. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 35: 1127-1132. (Pubitemid 350206444)
23. McGeer, P. L., and E. G. McGeer. 2008. Glial reactions in Parkinson's disease. Mov. Disord. 23: 474-483.
24. Nagatsu, T., and M. Sawada. 2005. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11: 999-1016. (Pubitemid 40331301)
25. Saijo, K., B. Winner, C. T. Carson, J. G. Collier, L. Boyer, M. G. Rosenfeld, F. H. Gage, and C. K. Glass. 2009. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137: 47-59.
26. Beal, M. F. 2001. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2: 325-334.
27. Bluthé, R. M., A. Bristow, J. Lestage, C. Imbs, and R. Dantzer. 2001. Central injection of interleukin-13 potentiates LPS-induced sickness behavior in rats. Neuroreport 12: 3979-3983. (Pubitemid 33152437)
28. Shin, W. H., D. Y. Lee, K. W. Park, S. U. Kim, M. S. Yang, E. H. Joe, and B. K. Jin. 2004. Microglia expressing interleukin-13 undergo cell death and contribute to neuronal survival in vivo. Glia 46: 142-152. (Pubitemid 38596180)
29. Yang, M. S., K. A. Ji, S. B. Jeon, B. K. Jin, S. U. Kim, I. Jou, and E. Joe. 2006. Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J. Immunol. 177: 1323-1329. (Pubitemid 44036639)
30. Yang, M. S., E. J. Park, S. Sohn, H. J. Kwon, W. H. Shin, H. K. Pyo, B. Jin, K. S. Choi, I. Jou, and E. H. Joe. 2002. Interleukin-13 and -4 induce death of activated microglia. Glia 38: 273-280.
31. Joshi, B. H., C. Hogaboam, P. Dover, S. R. Husain, and R. K. Puri. 2006. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam. Horm. 74: 479-504.
32. Kuperman, D. A., and R. P. Schleimer. 2008. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr. Mol. Med. 8: 384-392.
33. Wills-Karp, M. 2004. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202: 175-190. (Pubitemid 39576912)
34. Brown, K. D., S. M. Zurawski, T. R. Mosmann, and G. Zurawski. 1989. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J. Immunol. 142: 679-687. (Pubitemid 19039994)
35. Minty, A., P. Chalon, J. M. Derocq, X. Dumont, J. C. Guillemot, M. Kaghad, C. Labit, P. Leplatois, P. Liauzun, B. Miloux, et al. 1993. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248-250. (Pubitemid 23093630)
36. Morgan, J. G., G. M. Dolganov, S. E. Robbins, L. M. Hinton, and M. Lovett. 1992. The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes. Nucleic Acids Res. 20: 5173-5179.
37. McKenzie, A. N., J. A. Culpepper, R. de Waal Malefyt, F. Brière, J. Punnonen, G. Aversa, A. Sato, W. Dang, B. G. Cocks, S. Menon, et al. 1993. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA 90: 3735-3739. (Pubitemid 23111442)
38. Park, K. W., H. H. Baik, and B. K. Jin. 2008. Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr Aging Sci 1: 192-201.
39. Park, K. W., H. H. Baik, and B. K. Jin. 2009. IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo. J. Immunol. 183: 4666-4674.
40. Yadav, M. C., E. M. Burudi, M. Alirezaei, C. C. Flynn, D. D. Watry, C. M. Lanigan, and H. S. Fox. 2007. IFN-γ-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia 55: 1385-1396. (Pubitemid 47328941)
41. Van Den Eeden, S. K., C. M. Tanner, A. L. Bernstein, R. D. Fross, A. Leimpeter, D. A. Bloch, and L. M. Nelson. 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157: 1015-1022. (Pubitemid 36628805)
42. Bower, J. H., D. M. Maraganore, B. J. Peterson, J. E. Ahlskog, and W. A. Rocca. 2006. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67: 494-496. (Pubitemid 44214979)